HALOZYME THERAPEUTICS, INC. — Director's Dealing 2021

Mar 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HALOZYME THERAPEUTICS, INC. (HALO)
CIK: 0001159036
Period of Report: 2021-03-01

Reporting Person: Torley Helen (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock	M	50000	$14.66	Acquired	587160	Direct
2021-03-01	Common Stock	S	16110	$45.583	Disposed	571050	Direct
2021-03-01	Common Stock	S	33890	$46.4772	Disposed	537160	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-01	Option to Purchase Common Stock	$14.66	M	50000	Disposed	2024-01-06	Common Stock (50000)	Direct

Footnotes

F1: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1.

F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $45.12 to $46.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $46.13 to $46.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014.